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Edited by Laszlo NagyAbstract We studied the eﬀects of cytostatic drugs on porcine
coronary artery spindle-shaped (S) and rhomboid (R) smooth
muscle cell (SMC) biological activities related to intimal thick-
ening (IT) formation.
Imatinib, and to a lesser extent curcumin, decreased prolifer-
ation of S- and R-SMCs and migratory and urokinase activities
of R-SMCs more eﬃciently compared with cyclosporine plus
rapamycin. Imatinib increased the expression of a-smooth mus-
cle actin in both SMC populations and that of smoothelin in S-
SMCs. It decreased S100A4 expression in R-SMCs.
By promoting SMC quiescence and diﬀerentiation imatinib
and curcumin may represent valid candidates for restenosis pre-
ventive and therapeutic strategies.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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An important limitation of percutaneous transluminal coro-
nary angioplasty with or without stent implantation is the sig-
niﬁcant restenosis observed in 20–40% of patients (for review
see [1]). One of the major breakthrough in restenosis preven-
tion has been the development of drug-eluting stents liberating
cytostatic compounds in order to inhibit the undesired smooth
muscle cell (SMC) accumulation within the intima [1]. Among
them, rapamycin is widely used in clinical settings [2]; it forms
a complex with FK506 binding protein, which in turn binds to
mammalian target of rapamycin inhibiting cell cycle progres-
sion [3]. Other cytostatic molecules such as cyclosporine A,
imatinib and curcumin are emerging as alternative drugs for
stent coating. Cyclosporine A forms a complex with cyclophy-
lin, which in turn blocks calcineurin and inhibits nuclear factor
of activated T-cells-induced gene [3]. Imatinib is an inhibitor of
several protein-tyrosine kinase receptors such as BCR-ABL
oncoprotein [4], c-KIT receptor [5] and platelet-derived growth*Corresponding author. Fax: +41 22 379 5746.
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doi:10.1016/j.febslet.2007.11.060factor (PDGF) receptor [6]. Curcumin, a phenolic agent, has
been shown to reduce SMC proliferation and migration [7,8].
During restenosis as well as during atheromatous plaque
development SMCs migrate from the media toward the intima
where they proliferate, undergo characteristic phenotypic
changes and are responsible for extracellular matrix accumula-
tion (for review see [9]). Alternative to the predominant
hypothesis that all SMCs of the media participate to this pro-
cess [9] the concept of SMC heterogeneity suggests that a pre-
disposed SMC subpopulation is responsible for intimal
thickening (IT) formation (for review see [10]). Our laboratory
has characterized two distinct SMC populations from the nor-
mal media of porcine coronary artery: spindle-shaped (S)
exhibiting a classical hills-and-valleys growth pattern and
rhomboid (R), growing as a monolayer and displaying en-
hanced proliferative, migratory and proteolytic activities as
well as poor level of diﬀerentiation compared with S-SMCs
[11]. R-SMCs are predominantly recovered from the IT in-
duced after experimental stent implantation indicating that
they are crucial for arterial repair, and could represent an ath-
eroma-prone phenotype [11]. Recently we have reported that
S100A4 is a marker of R-SMCs in vitro and of SMCs located
in the atheromatous plaque and restenosis both in pig and man
[12].
The aim of the present work was to compare the eﬀects of
cytostatic drugs on phenotypic features of porcine coronary
artery S- and R-SMCs. We show that imatinib and, to a lesser
extent, curcumin decrease importantly proliferative, migratory
and proteolytic activities and increase diﬀerentiation level of
both SMC populations compared with cyclosporine and rapa-
mycin. Moreover, imatinib selectively increases smoothelin
expression. Our results extend the understanding of the mech-
anisms involved in the reduction of restenosis by cytostatic
drugs and may be useful in the planning of preventive and
therapeutic strategies based on imatinib and curcumin admin-
istration.2. Materials and methods
2.1. Cell culture
SMC populations were isolated from the left anterior descending
coronary artery media of 8-month-old domestic crossbred pigs. S-
SMCs were isolated by enzymatic digestion and R-SMCs by tissue
explantation [11]. SMCs were cultured in Dulbeccos modiﬁed Eagleblished by Elsevier B.V. All rights reserved.
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serum (FCS; Amimed; France) and used from passage 7 to 12.
2.2. Drug treatment
For cell proliferation assays, SMCs were treated with one of the fol-
lowing drugs: 0.001 or 0.01 lg/ml imatinib, 2.5 or 5 lg/ml curcumin; 10
or 100 nM cyclosporine A and rapamycin used simultaneously at the
same concentration and referred subsequently to cyclosporine plus
rapamycin. For cell migration and urokinase activity assays as well
as immunoblotting, the highest drug doses were used. Imatinib and
rapamycin were dissolved in dimethylsulfoxide and cyclosporine in
ethanol. The corresponding amounts of vehicles were used in control
conditions.
2.3. Cell proliferation
Cells (n = 4 for S-SMCs and n = 6 for R-SMCs) were plated at a
density of 70 cells/mm2 in 100 mm culture dishes containing DMEM
supplemented with 10% FCS. Twenty-four hours after plating, cells
were incubated with drugs or vehicle in DMEM plus 10% FCS. Med-
ium was changed every 2 (for cyclosporine plus rapamycin) or 3 (for
imatinib and curcumin) days. Cells were harvested after 6 days of treat-
ment and counted using a hemocytometer. Cell viability was estimated
by Trypan blue exclusion test.
2.4. Cell migration and urokinase activity
Cell migration was analyzed by using an ‘‘in vitro wound’’ model in
conﬂuent culture of R-SMCs (n = 3) [11]. Zymographic assays were
performed on cell lysates of R-SMCs (n = 3) [11].
2.5. SDS–PAGE and immunoblotting
Cultured SMCs (n = 6 for each phenotype) were processed for SDS–
PAGE [11]. Protein loading was controlled on Coomassie blue stained
SDS–PAGE. For immunoblotting, the following antibodies were used:
mouse monoclonal IgG2a recognizing a-smooth muscle actin (a-SMA;
clone 1A4) [13], rabbit polyclonal IgGs recognizing smooth muscle
myosin heavy chains (SMMHCs; BT-562, Biomedical Technologies,Fig. 1. Bar graph showing the eﬀect of imatinib (IMTB), curcumin (CURC)
S- (open bars) and R- (ﬁlled bars) SMCs compared with their respective cont
decrease proliferation of S- and R-SMCs compared with control conditions w
only of S-SMCs. Note that imatinib exhibits a more pronounced eﬀect on R-
compared with control conditions. ###P < 0.001 in S- vs. R-SMCs.Stoughton, Mass), mouse monoclonal IgG1 recognizing smoothelin
A and B (clone R4A) [14], rabbit polyclonal IgGs (Dako, Copenhagen,
Denmark) or mouse monoclonal IgM recognizing S100A4 (clone 4B4)
[12]. Enhanced chemiluminescence was used for detection.
2.6. Statistical analysis
Results are expressed as a mean percentage of control conditions
±S.E.M. and analyzed by independent Student t-test. Diﬀerences were
considered statistically signiﬁcant at values of P < 0.05.3. Results
3.1. Cell proliferation
In preliminary experiments we selected the doses of the dif-
ferent compounds that inﬂuenced optimally cell proliferation
without toxic eﬀects. Rapamycin and cyclosporine used alone
showed less strong eﬀects on SMC proliferation compared
with both curcumin and imatinib (data not shown), thus we
decided to concentrate on the last two drugs and compare each
of them with a combination of the ﬁrst two drugs (see below).
After 6 days of culture in control conditions, cells were close to
conﬂuence and no diﬀerence was observed between S- and R-
SMC cell number (112 ± 17% in R- compared with S-SMCs).
After 6 days of treatment, imatinib at low and high concentra-
tions markedly decreased proliferation of both SMC popula-
tions i.e. to 65 ± 7% for S-SMCs (P < 0.05) and to 48 ± 7%
for R-SMCs (P < 0.05) at 0.001 lg/ml, and to 56 ± 5% for S-
SMCs (P < 0.01) and to 23 ± 3% for R-SMCs (P < 0.001) at
0.01 lg/ml compared with control conditions (Fig. 1). Interest-
ingly, the reduced proliferation observed at the highest dose
was signiﬁcantly more pronounced for R-SMCs than for S-and cyclosporine plus rapamycin (Cy + Ra) on proliferative activity of
rol. Imatinib at 0.001 and 0.01 lg/ml and curcumin at 5 lg/ml strongly
hereas cyclosporine plus rapamycin at 100 nM decreases proliferation
than on S-SMCs. *P < 0.05, **P < 0.01 and ***P < 0.001 in treated cells
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ml did not aﬀect proliferation of both SMC populations
whereas at 5 lg/ml it decreased proliferation of S-SMCs to
40 ± 7% (P < 0.01) and of R-SMCs to 43 ± 11% (P < 0.01).
Cyclosporine plus rapamycin signiﬁcantly decreased prolifera-
tion of S-SMCs to 65 ± 11% (P < 0.01) at 100 nM whereas it
had no eﬀect at 10 nM. It did not aﬀect proliferation of R-
SMCs at any tested doses. The number of dead cells measured
by trypan blue exclusion test was negligible in all conditions
studied (<1% of total cell number).
3.2. Cell migration and urokinase activity
Cell migration assay and urokinase activity were performed
on R-SMCs, which exhibit a higher migratory capacity com-
pared with S-SMCs [11]. Imatinib (0.01 lg/ml) and to a lesser
extent curcumin (5 lg/ml) markedly reduced migration ofFig. 2. Bar graphs showing the eﬀect of imatinib (IMTB), curcumin
(CURC) and cyclosporine plus rapamycin (Cy + Ra) on migratory (A)
and urokinase (B) activities of R-SMCs. A representative zymogram of
urokinase activity is shown in panel B. Imatinib and to a lesser extent
curcumin decrease migration and urokinase activities of R-SMCs
compared with control condition. Cyclosporine plus rapamycin has no
eﬀect. *P < 0.05, **P < 0.01 and ***P < 0.001.R-SMCs to 49 ± 13% (P < 0.01) and to 77 ± 1% (P < 0.01),
respectively (Fig. 2A). Cyclosporine plus rapamycin
(100 nM) did not show an eﬀect on R-SMC migration. Imati-
nib strongly decreased urokinase activity to 21 ± 8%
(P < 0.001) whereas curcumin decreased it to 57 ± 13%
(P < 0.05) (Fig. 2B); cyclosporine plus rapamycin had no eﬀect
on urokinase activity.
3.3. SMC diﬀerentiation marker and S100A4 expression
Immunoblotting conﬁrmed that a-SMA expression is higher
in S-SMCs compared with R-SMCs in control conditions
(185 ± 7% in S- compared with R-SMCs, P < 0.001, Fig. 3)
[11]. Imatinib (0.01 lg/ml) increased a-SMA expression to
132 ± 3% in S-SMCs (P < 0.001) and to 146 ± 21% in R-SMCs
(P < 0.05). Curcumin (5 lg/ml) did not aﬀect a-SMA expres-
sion in both SMC populations. Cyclosporine plus rapamycin
(100 nM) signiﬁcantly decreased a-SMA expression in S-SMCs
to 77 ± 5% (P < 0.001) whereas it had no eﬀect on R-SMCs.
Immunoblotting conﬁrmed that S100A4 is strongly ex-
pressed in R-SMCs (Fig. 4) [12]. Imatinib decreased S100A4
expression in R-SMCs to 41 ± 3% (P < 0.001) whereas curcu-
min had no eﬀect. Cyclosporine plus rapamycin decreased
S100A4 expression to 76 ± 18% (P < 0.05). S100A4 was not
detectable in S-SMCs [12] and was not aﬀected by any tested
drugs.Fig. 3. Bar graph and representative immunoblot showing the eﬀect of
imatinib (IMTB), curcumin (CURC) and cyclosporine plus rapamycin
(Cy + Ra) on a-SMA expression of S- (open bars) and R- (ﬁlled bars)
SMCs compared with their respective control. Imatinib increases a-
SMA expression in both SMC populations compared with control
conditions, curcumin has no eﬀect and cyclosporine plus rapamycin
signiﬁcantly decreases it only in S-SMCs. *P < 0.05 and ***P < 0.001.
Fig. 4. Bar graph and representative immunoblot showing the eﬀect of
imatinib (IMTB), curcumin (CURC) and cyclosporine plus rapamycin
(Cy + Ra) on S100A4 expression in R-SMCs. Imatinib and to a lesser
extent cyclosporine plus rapamycin decrease S100A4 expression
compared with control condition whereas curcumin has no eﬀect.
*P < 0.05 and ***P < 0.001.
Fig. 6. Bar graph and representative immunoblot showing the eﬀect of
imatinib (IMTB), curcumin (CURC) and cyclosporine plus rapamycin
(Cy + Ra) on smoothelin expression in S-SMCs. Imatinib drastically
increases smoothelin expression compared with control condition
while the other treatments have no eﬀect. **P < 0.01.
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R-SMCs in control conditions (492 ± 89% in S- compared with
R-SMCs, P < 0.05, Fig. 5) [11]. In both SMC populations,
none of the drugs modiﬁed its expression. Smoothelin B was
detected only in S-SMCs [11]. Imatinib drastically increased
its expression to 284 ± 42% (P < 0.01) whereas the other drugs
had no eﬀect. In R-SMCs, smoothelin was not detected in con-
trol conditions and its expression was not changed by any of
the drugs (Fig. 6).Fig. 5. Bar graph and representative immunoblots showing the eﬀect
of imatinib (IMTB), curcumin (CURC) and cyclosporine plus rapa-
mycin (Cy + Ra) on SMMHC expression in S- (open bars) and R-
(ﬁlled bars) SMCs compared with their respective control. SMMHC
expression is not modulated by any tested drugs.4. Discussion
The present study shows that among the tested cytostatic
drugs, imatinib is the most eﬃcient to maintain or induce
SMC biological features typical of the diﬀerentiated quiescent
phenotype. Importantly, it aﬀects preferentially R-SMCs, the
phenotype allegedly related to IT formation, by reducing their
proliferative, migratory and proteolytic activities. These eﬀects
are associated with an increased expression of diﬀerentiation
markers and with a decreased expression of S100A4.
Previous work has established that imatinib decreases
PDGF-induced rat aortic SMC proliferation and motility by
inhibiting PDGF receptor autophosphorylation in dose depen-
dent manner [6]. It inhibits G1 to S cell cycle progression in hu-
man SMCs [15]. In vivo, it reduces intimal SMC accumulation
after endothelial injury of rat carotid artery [6]. We have ex-
tended to the porcine coronary artery SMC populations the
observation that imatinib is a strong inhibitor of proliferation
and migration and show that it acts preferentially on R-SMCs.
Imatinib has been shown to reduce proliferation of SMCs to a
greater extent than that of endothelial cells [16,17]. It has been
reported that imatinib fails to aﬀect IT formation after stent
implantation in porcine coronary artery [17]; however the
authors did not provide evidence for achievement of a thera-
peutic dose delivery in target organs [17].
Surprisingly, imatinib strongly increased smoothelin expres-
sion in S-SMCs without changing SMMHC expression,
whereas in general these SMC markers behave similarly
[18,19]. Two smoothelin isoforms have been described: A
(59 kDa) mainly expressed in visceral SMCs and B (110 kDa)
predominantly expressed in vascular SMCs [18,19]. Smooth-
elin has been shown to represent a marker of late SMC diﬀer-
entiation; its expression ceases when SMCs are placed in
culture with the exception of porcine coronary artery S-SMCs
[11] and importantly decreases when SMCs accumulate in IT
[18,19]. Thus, imatinib appears to stimulate terminal SMC dif-
ferentiation. It may also represent a new tool for the study of
smoothelin expression regulation in porcine SMCs.
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lytic activities of SMCs; however it did not modulate a-SMA,
SMMHCs, smoothelin or S100A4 expression in these cells.
Using doses similar to those described in our study Yang
et al. [8] have shown that curcumin reduces motility, collagen
synthesis and PDGF receptor b autophosphorylation in rat
aortic SMCs stimulated with PDGF. In vivo, curcumin re-
duces IT formation in balloon injured rat carotid artery.
Rapamycin is known to reduce in vitro SMC proliferation
and migration in rats, humans and pigs [20]. In porcine coro-
nary artery, drug-eluting stents coated with rapamycin inhibit
IT formation 28 days after treatment [21,22] but is much less
eﬃcient at long-term follow-up [21,22]. Our results demon-
strate that cyclosporine plus rapamycin reduces proliferation
of S-SMCs at the highest tested dose; surprisingly, this is asso-
ciated with a decreased a-SMA expression. Thus rapamycin,
which is the most common molecule used in drug-eluting stents
in clinical settings [2], does not target the atheroma-prone phe-
notype but exhibits a tendency to modulate S-SMCs toward
the R-phenotype failing to favourably modify SMC pheno-
type.
In conclusion, our study brings new experimental data in
support of the assumption that imatinib and to a lesser extent
curcumin represent good candidate molecules for tests aiming
at restenosis prevention as far as their action on SMC pheno-
typic and biological features is concerned. Obviously only
in vivo tests will determine the suitability of these drugs for
clinical development.
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